KLI

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.

Metadata Downloads
Publisher
LANCET ONCOLOGY
Language
영어
ISSN
1470-2045
Citation Volume
21
Citation Number
12
Citation Start Page
1574
Citation End Page
1588
Appears in Collections:
Medicine > Medicine
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.